The present invention discloses an edaravone pharmaceutical composition comprising edaravone or its salt and mannitol and its hypoglostical preparation. The sublingual preparation can avoid the first pass effect of the liver, and has good advantages such as good stability, easy transport, and convenient use.No selection
展开▼
